Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 71

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Triple negative breast cancer

Recruiting

Study on NECVAX-NEO1 and Paclitaxel Albumin-Bound for Patients with Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Necvax-Neo1
  • Sponsor:NEC Bio Therapeutics GmbH

Ewing's sarcoma

Recruiting

Study on the Effectiveness and Safety of Naxitamab for Patients with Refractory Ewing's Sarcoma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Naxitamab
  • Sponsor:Instytut Matki I Dziecka

Triple negative breast cancer

Recruiting

Study of Atezolizumab, Vinorelbine, and Cyclophosphamide for Patients with Advanced Triple Negative Breast Cancer Previously Treated with Anti-PD-L1/PD-1

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Acute myeloid leukaemia

Recruiting

Study on Mocravimod for Adults with Acute Myeloid Leukemia Undergoing Stem Cell Transplant

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mocravimod
  • Sponsor:Priothera S.A.S.

Breast cancer

Recruiting

Study of Fertility Preservation Using Tamoxifen, Follitropin Beta, Cetrorelix and Choriogonadotropin Alfa in Women with Breast Cancer Before Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cetrorelix
  • Sponsor:Institut De Cancerologie De L Ouest

Colorectal cancer metastatic

Recruiting

Study of Atezolizumab with Drug Combination for Patients with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione GONO G.I.

Pancreatic carcinoma

Recruiting

Study on Sequential Treatment with Gemcitabine, Paclitaxel, and FOLFIRINOX for Patients with Locally Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Institut Regional Du Cancer De Montpellier

Ovarian cancer+2

Recruiting

Study on the Safety and Tolerability of TUB-040 for Patients with Platinum-Resistant Ovarian Cancer or Relapsed/Refractory Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:TUB-040
  • Sponsor:Gilead Sciences Inc.

Follicular lymphoma

Recruiting

Study of tazemetostat combined with lenalidomide and rituximab in adult patients with relapsed or refractory follicular lymphoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Epizyme Inc.

Squamous cell carcinoma of skin

Recruiting

Study of Nivolumab and Nivolumab Plus Relatlimab for Patients with Advanced or Metastatic Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Gemeinnutzige Salzburger Landes kliniken Betriebsgesellschaft mbH

Squamous cell carcinoma of lung

Recruiting

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Zanidatamab with Cisplatin and Gemcitabine for Advanced HER2 Positive Biliary Tract Cancer Patients

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.